设计,合成和生物活性评估 改性维穆拉费尼比类似物
Fabiana Sélos Guerra1, Rosana Helena Coimbra Nogueira de Freitas2,3, Florina Moldovan4
1Laboratório de Farmacologia da Dor e da Inflamação, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
研究人员开发了新的维穆拉费尼比类药物来对抗转移性黑色素瘤. 一种类型,RF-86A,显示出有前途的抗扩散和抗转移作用,抑制参与瘤扩散的关键酶.
科学领域:
- 癌症学
- 医学化学
背景情况:
- 转移性黑色素瘤是一种具有不良结果的侵袭性癌症.
- 在 40% 的黑色素瘤中存在 BRAF V600E 突变,这些黑色素瘤是韦穆拉费尼的向.
- 需要开发更好的治疗策略.
研究的目的:
- 设计,合成和表征新型维穆拉费尼比类似物.
- 增强对人类黑色素瘤细胞的抗扩散和抗转移作用.
- 确定比维穆拉费尼布更高的疗效和选择性.
主要方法:
- 合成和表征五种维穆拉费尼比类似物 (RF-86A,RF-87A,RF-94A,RF-94B,RF-96B).
- 在BRAF V600E突变A375细胞中评估抗增殖活性 (IC50).
- 使用HEK293T细胞的选择性评估和通过迁移测定和发血镜的MMP-2/MMP-9抑制.
主要成果:
- 所有类型的药物都在A375细胞中诱导了亡;RF-86A显示了最低的IC50,与vemuarafenib相比.
- 在新型化合物中,RF-86A具有最高的选择性指数.
- 类似药物显著抑制了矩阵金属蛋白酶MMP- 2和MMP- 9,而非维穆拉芬尼.
结论:
- 维穆拉费尼的结构修改可以提高治疗效果.
- 新的类似物显示出克服黑色素瘤中维穆拉芬尼抗性的潜力.
- 这些化合物代表了晚期黑色素瘤治疗的有希望的策略.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drug Discovery: Overview
